NICE Recommends EndoPredict®
December 19, 2018

Assessment finds EndoPredict clinically effective and cost-effective

View News Release

Important New Data Presented at 2018 San Antonio Breast Cancer Symposium
December 7, 2018

EndoPredict® is the Only Test to Answer Three Critical Questions: Risk of Breast Cancer Recurrence, Benefits of Chemotherapy and Who Can Forgo Extended Endocrine Therapy

View News Release

New Data Differentiate Prognostic Value of Four Multigene Expression Tests
February 15, 2018

Published Comparison of Four Breast Prognostics

View News Release

EndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem
August, 17, 2017

Brings Total Coverage to Over 90 Percent of Breast Cancer Patients

View News Release

Myriad Launches the EndoPredict® Test in the United States for Patients with Breast Cancer
March 13, 2017

Second-Generation Test Provides More Accurate 10-Year Recurrence Risk for Patients Diagnosed with ER+ HER2- Early-Stage Breast Cancers

View News Release

The EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans
January 6, 2017

Coverage Decisions Expand Access to More Than 32 Million Patients

View News Release

EndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street
January 5, 2017

The Level of Evidence for EndoPredict Consistent with that of First-Generation Test

View News Release

The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence
December 9, 2016

View News Release

Myriad Acquires Sividon Diagnostics: Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict®
May 31, 2016

View News Release


For more information and content, go to
EndoPredict®